Yoshikazu Tamori

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Objective The adverse effects of selective sodium-glucose co-transporter 2 (SGLT2) inhibitors generally appear within about two or three months after treatment initiation in Japan. Therefore, we investigated the impact of tofogliflozin, a class of SGLT2 inhibitors, on glycemic control and body composition during this period in Japanese patients with type 2(More)
  • 1